Acute myeloid leukemia in patients more than 50 years of age: special considerations in diagnosis, treatment, and prognosis.
Although most patients with acute myeloid leukemia are more than 50 years of age and age is known to be an adverse prognostic factor, relatively few studies have been conducted to determine the optimum treatment strategy for the older patient. This report suggests that, until definitive studies are conducted in this age group, intensive chemotherapy should always be considered if the older patient's overall status and desires are consistent with this approach. Other factors, specifically cytogenetic and cell-surface marker findings, provide prognostic information, independent of age, and should also be considered during patient management.